.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Cipla
Deloitte
McKesson
Julphar
Mallinckrodt
Novartis
Healthtrust
QuintilesIMS

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,985,322

« Back to Dashboard

Which drugs does patent 5,985,322 protect, and when does it expire?


Patent 5,985,322 protects PROZAC WEEKLY and is included in one NDA.

Protection for PROZAC WEEKLY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-eight patent family members in forty-five countries.

Summary for Patent: 5,985,322

Title: Method for the treatment of CNS disorders
Abstract:An improved method for the treatment of central nervous system disorders comprises treating patients with an enteric fluoxetine formulation.
Inventor(s): Anderson; Neil R. (West Lafayette, IN), Harrison; Roger F. (Zionsville, IN), Lynch; Daniel F. (Indianapolis, IN), Oren; Peter L. (Fishers, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/265,610
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
LillyPROZAC WEEKLYfluoxetine hydrochlorideCAPSULE, DELAYED REL PELLETS;ORAL021235-001Feb 26, 2001ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,985,322

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,910,319 Fluoxetine enteric pellets and methods for their preparation and use► Subscribe
RE39030Fluoxetine enteric pellets and methods for their preparation and use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,985,322

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
El Salvador1998000052► Subscribe
Slovenia9800128► Subscribe
Singapore72805► Subscribe
Sweden522914► Subscribe
Sweden9801336► Subscribe
Russian Federation2164405► Subscribe
Serbia49827► Subscribe
Yugoslavia16598► Subscribe
Romania120043► Subscribe
Portugal102152► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Colorcon
Medtronic
Federal Trade Commission
Cipla
Cerilliant
Merck
Teva
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot